Roche arthritis drug 'beats top-selling rival'
Zurich, June 6, 2012
Roche said on Wednesday that a trial had shown its rheumatoid arthritis drug RoActemra was more effective in reducing swelling and tenderness in joints than Abbott Laboratories' top-selling Humira when given as a single treatment.
Humira is one of the world's top-selling medicines, garnering more than $8 billion per year, but is facing growing competition from other therapies including a pill being developed by Pfizer.
Karsten Jung, Head GPS Immunology at Roche said the aim of the trial was to give comparative data to doctors to help them to decide in favour of RoActemra, also known as Actemra outside of Europe, when prescribing treatment.
"Among a treatment environment of nine different medicines, it is very difficult to make an individual treatment decision for the physician. They are looking for reasons why they should choose one over the other," Jung told Reuters.
Roche's drug has been approved in US and Europe for use in patients who are either intolerant to or have failed to respond to other medicines to treat inflammation.
Roche said the results of the 24-week study of 326 patients, will be presented on June 8 at the European League Against Rheumatism (EULAR) meeting in Berlin.
About 1 percent of the world's adult population has rheumatoid arthritis, a potentially crippling condition in which the body's own immune system attacks the joints. - Reuters
More Health & Environment Stories
- One more dead from SARS virus in Saudi
- Dubai Healthcare City inks deal with UAE universities
- University of Ain Shams opens MS treatment unit
- Bahrain's humidity could ease water crisis
- Visibility in Bahrain forecast to improve
- Bahrain-India venture plans hospitals in GCC
- Seha launches new health initiative
- Veolia backs Oman waste management meet
- Obesity rate at 72pc among Saudi adults
- Bahrain ideal for artificial rain experiment
- Riyadh 'among most polluted cities'
- CGM acquires 3 European healthcare IT providers
- The age of genomic medicine dawns, finally
- Over 300 exhibitors for Saudi healthcare event
- Mackeen unveils document management solution
- Seha opens new clinics in Abu Dhabi, Al Ain
- SARS virus claims one more victim in Saudi
- New support group comes to overeaters' rescue
- RAK Hospital launches urinary clinic for women
- NBAD backs Emiratis on Antarctica trip
- Cut sugar intake drastically urges WHO
- Al khaliji to fund Qatar recycling plant
- Qatar researcher in 360km breast cancer run
- New facilitator to open in DHCC
- Many countries lack capacity to prevent hearing loss
- QUIT NOW: Passive smoking hurts kids' arteries
- San Francisco to ban plastic water bottles
- GSK wins home toothpaste award for Sensodyne
- E-integration vital to GCC healthcare industry
- Fakih IVF unveils two new genetic tests